Dr. Theodore W. Laetsch
Claim this profileChildren's Hospital of Philadelphia
Expert in Cancer
Expert in Soft Tissue Sarcoma
33 reported clinical trials
48 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
NTRK1 positive
NTRK positive
2Soft Tissue Sarcoma
Global LeaderStage IV
FET fusion positive
EWS-FLI1 fusion positive
Affiliated Hospitals
Clinical Trials Theodore W. Laetsch is currently running
Selpercatinib
for Thyroid Cancer
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Recruiting1 award Phase 24 criteria
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting1 award Phase 1 & 213 criteria
More about Theodore W. Laetsch
Clinical Trial Related2 years of experience running clinical trials · Led 33 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Theodore W. Laetsch has experience with
- Larotrectinib
- Selpercatinib
- Gemcitabine
- Atezolizumab
- Vincristine
- Ramucirumab
Breakdown of trials Theodore W. Laetsch has run
Cancer
Soft Tissue Sarcoma
Uterine Tumors
Osteosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Theodore W. Laetsch specialize in?
Theodore W. Laetsch focuses on Cancer and Soft Tissue Sarcoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are NTRK1 positive.
Is Theodore W. Laetsch currently recruiting for clinical trials?
Yes, Theodore W. Laetsch is currently recruiting for 11 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Theodore W. Laetsch has studied deeply?
Yes, Theodore W. Laetsch has studied treatments such as Larotrectinib, Selpercatinib, Gemcitabine.
What is the best way to schedule an appointment with Theodore W. Laetsch?
Apply for one of the trials that Theodore W. Laetsch is conducting.
What is the office address of Theodore W. Laetsch?
The office of Theodore W. Laetsch is located at: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the Children's Hospital of Philadelphia.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.